Your Health, We Care
1. Previously Untreated Mantle Cell LymphomaAcalabrutinib (CALQUENCE) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
2. Previously Treated Mantle Cell LymphomaAcalabrutinib (CALQUENCE) is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
3. Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaAcalabrutinib (CALQUENCE) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA，2025.01
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
